Segments - Epilepsy Monitoring Devices Market by Products (Wearable and Conventional), End-users (Hospitals, Ambulatory Surgery Centers& Clinics, Neurology Centers, Diagnostic Centers, and Home Care Settings), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The global epilepsy monitoring devices market size was valued at USD 511.98 Million in 2022 and is expected to surpass USD 774.06 Million by 2031, expanding at a CAGR of 4.7% during the forecast period, 2023–2031.
An increase in the prevalence of epilepsy, growing demand for ambulatory healthcare, increasing use of wearables, and rising need for continuous monitoring are primary factors driving the epilepsy monitoring devices market.
Epilepsy is a life-threatening disease. It affects the brain and is non-communicable. Epilepsy affects 50 million individuals globally, according to a WHO report. The vast majority of them (almost 80%) live in low- and middle-income countries. With proper care; however, 70% of them might become seizure-free. Epilepsy causes a significant rate of premature death.
As a result, effective monitoring is critical. If the disease is detected early enough, it can be treated effectively. Epilepsy is a neurological illness characterized by recurring sensory disturbances, loss of consciousness or convulsions, all of which are linked to irregular electrical activity in the brain and can result in seizures and other significant problems.
It is tough for parents to keep a track on the condition when children develop epilepsy. Devices that assist parents and persons with epilepsy have been developed by healthcare companies. These gadgets can monitor seizures and protect users from catastrophic adverse effects. Bracelets, watches, anti-suffocation cushions, and mattress devices are all included.
These devices are not a cure for the illness, but they help with anxiety. Electroencephalogram (EEG) devices are used to diagnose brain problems using epilepsy monitoring devices. The EEG is a non-invasive electrophysiological monitoring tool for detecting brain electrical activity.
Epilepsy affects an estimated five million individuals worldwide each year, according to the World Health Organization. Epilepsy is diagnosed in 49 per 100,000 people in high-income nations each year, according to estimates. This rate can be as high as 139 per 100,000 in low- and middle-income nations.
This is most likely owing to an increased risk of endemic diseases like malaria and neurocysticercosis, a higher frequency of road traffic and birth-related injuries, differences in medical infrastructure, and the availability of preventative health initiatives and accessible care.
Growing prevalence of epilepsy is expected to boost the market in the coming years.
Increasing preference for ambulatory healthcare and growing use of wearables are projected to drive the market during the forecast period.
Rising need for continuous monitoring is anticipated to drive the market in the coming years.
Growing awareness of neurodegenerative diseases, such as epilepsy across the globe is expected to boost the market during the forecast period.
High cost associated with the complex epilepsy monitoring procedures and devices is a major factor that is expected to hinder the market during the forecast period.
Growing need for non-invasive and minimally invasive devicesis expected to offer lucrative opportunities for key playersin the coming years.
The report on the global epilepsy monitoring devices market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Epilepsy Monitoring Devices Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Products (Wearable and Conventional), End-users (Hospitals, Ambulatory Surgery Centers& Clinics, Neurology Centers, Diagnostic Centers, and Home Care Settings) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered |
Natus Medical Incorporated., Compumedics Limited, Empatica Inc.,Medtronic, Masimo., Boston Scientific Corporation, Drägerwerk AG & Co. KGaA, LivAssured B.V., Neurosoft, and Lifelines Neuro |
Based on products, the epilepsy monitoring devices market is divided into wearable devices and conventional devices. The conventional devices segment is expected to account for a key share of the market during the forecast period due to increasing awareness of neurodegenerative diseases including epilepsy and growing need for continuous monitoring and minimally invasive and non-invasive devices.
In terms of end-users, the market is segregated into hospitals, ambulatory surgery centers & clinics, neurology centers, diagnostic centers, and home care settings. The hospitals segment is anticipated to account for a significant share of the market during the forecast period, as people prefer to visit hospitals and clinics for diagnosis.
On the basis of regions, the global epilepsy monitoring devices market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
The market in Asia Pacific is estimated to expand at a rapid CAGR during the forecast period due to rising medical tourism, implementation of new ICT guidelines in Japan, investments and reforms to modernize China's healthcare infrastructure, the presence of a large target patient population, growing awareness about epilepsy, and rising healthcare expenditure in emerging countries such as China and India.
Key players in the epilepsy monitoring devices market include Natus Medical Incorporated., Compumedics Limited, Empatica Inc.,Medtronic, Masimo., Boston Scientific Corporation, Drägerwerk AG & Co. KGaA, LivAssured B.V., Neurosoft, and Lifelines Neuro.